Together, these modifications produce a compound with substantially lower systemic plasma clearance than GHRP-6 approximately five-fold lower and moderate resistance to metabolic degradation, resulting in a more sustained and reproducible GH secretory response
This means that PBMs may favor medicines with high list prices and higher rebates when developing formularies, but no existing legislation requires these middlemen to disclose their negotiated rebates to patients, health insurance companies, state agencies, or employers. To be included in more favorable formulary positions, drug manufacturers are incentivized to raise their prices so that PBMs select the drugs that make them the most profit
from moderately severe depression to minimal symptoms, and was the only participant to not lose weight during the study, with an increase of 7 kg
Nature 2011 472(7341):57 - 63 K
In severe cases, reconstructive surgery may be required